Isolation and Culture of Myofiber-Derived Cells from the Extensor Digitorum Longus Muscle by Tietze, Ethan M
1 
 
ISOLATION AND CULTURE OF MYOFIBER-DERIVED CELLS FROM THE  
EXTENSOR DIGITORUM LONGUS MUSCLE 
 
 
 
 
 
  A Senior Project  
presented to 
the Faculty of the Biomedical and General Engineering Department 
California Polytechnic State University, 
San Luis Obispo 
 
 
 
 
 
In Partial Fulfillment 
of the Requirements for the Degree 
Bachelor of Science in Biomedical Engineering  
 
by 
Ethan M. Tietze 
February 2016 
 
 
 
2 
 
PROJECT INFORMATION 
 
TITLE: Isolation and Culture of Myofiber Derived Cells from 
 the  Extensor Digitorum Longus 
 
AUTHOR: Ethan Tietze 
 
DATE SUBMITTED: February 2016 
 
ADVISOR:  Trevor Cardinal, Associate Professor 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
3 
 
 
ABSTRACT 
Isolation and Culture of Satellite Cells from the Extensor Digitorum Longus 
Ethan M. Tietze 
Peripheral arterial occlusive disease (PAOD) involves distal artery occlusion by 
atherosclerotic plaques, which restricts blood flow and leads to ischemia in downstream 
tissues. Increased blood flow through preexisting collateral vessels leads to increased 
shear stress that triggers an outward remodeling of the vessel called arteriogenesis. In 
some cases this natural compensatory mechanism is able to sufficiently restore blood 
flow following arterial occlusion. However, for many individuals this process is 
insufficient to relieve peripheral ischemia, and patients experience intermittent 
claudication, or limb pain with locomotion or exercise. Without treatment, reduced blood 
flow can lead to tissue necrosis and potentially amputation. The efficacy of medication, 
such as drugs to lower cholesterol, is limited while surgical intervention is only available 
to a limited patient population. Supervised exercise therapy can improve important 
patient outcomes such as pain-free walking time and distance. Unfortunately, many 
patients fail to adhere to regimented exercise programs, limiting its functional efficacy. A 
potential alternative treatment approach is to stimulate or enhance arteriogenesis with cell 
therapy to recapitulate the beneficial effects of exercise therapy. Following exercise, 
resident muscle stem cells known as Satellite Cells (SCs) activate, repairing damaged 
muscle fibers and playing an important role in local angiogenesis. They and their progeny 
myoblasts, secrete a wide range of factors known to be involved in arteriogenesis and the 
recruitment of other cells involved in remodeling. As such, these cells are ideal 
candidates for transplantation. Before preliminary evaluation of these myogenic cells can 
be performed, a reliable source of these cells is required. Towards this goal, protocols 
were developed to obtain cells in sufficient numbers for transplantation. Whole Extensor 
Digitorum Longus (EDL) muscles were excised from mouse hindlimbs. Myofibers were 
isolated by collagenase digestion and trituration, and placed in specialized culture 
conditions to promote the adherence and selective growth of myogenic cells. In these 
conditions, SCs activate, migrate from myofibers, and proliferate. With increasing time in 
culture, especially following myofiber hypercontraction, SCs increasingly differentiate, 
limiting expansion and the availability of cells for transplantation. Future research will 
focus on improving culture conditions to inhibit differentiation and maintain sustained 
growth to improve the availability and in vivo behavior of isolated cells. Once sufficient 
cell numbers are obtained they will be transplanted into a mouse model of chronic 
peripheral ischemia to investigate their impact on collateral remodeling.   
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Chapter 1: Introduction 
1.1 Relevance:  Peripheral Arterial Occlusive Disease 
Peripheral Arterial Occlusive Disease (PAOD) is an ischemic disease characterized by 
the narrowing, or stenosis, of distal arteries, primarily in the lower extremities. Most 
commonly stenosis results from atherosclerotic plaques within arterial walls. With 
atherosclerotic progression, vessels can become increasing occluded, leading to ischemia 
in downstream tissues. Alternatively, thromboembolism can lead to a rapid onset of 
ischemic conditions  1–3. In the United States, over 8 million individuals have PAOD, 
with older individuals being disproportionately affected 4,5 ]. Patients with PAOD 
commonly present with temporary pain during activities such as walking or exercise, 
which is  
Figure 1. Peripheral Artery Occlusive Disease. In atherosclerosis, plaques develop 
within the walls of conduit arteries reducing blood flow and causing ischemia 
downstream tissues6. 
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termed intermittent claudication 2. If left untreated, blood flow can be further reduced 
until insufficient oxygen and nutrients are delivered even at rest, which is described as 
critical limb ischemia (CLI) 7. Within one year, 30% of individuals undergo amputation 
and another 25% of individuals die from coronary heart disease or stroke, which 
commonly present with PAOD.8. Although only a small percentage of patients reach this 
advanced stage of the disease, up to 50% of patients with PAOD experience leg 
symptoms that reduce mobility, leading to reduced reported quality of life, and increased 
rates of depression9 
First line treatments focus on the reduction risk factors for atherosclerosis, including 
cessation of smoking and management of blood pressure and cholesterol10. While these 
treatments are relatively low risk, they have a limited ability to address the underlying 
problem of reduced peripheral circulation. For example, cholesterol lowering medications 
may reduce the likelihood of plaque growth without substantially reducing plaque size11. 
Alternatively, surgical or endovascular procedures including bypass grafts and 
angioplasty, respectively, can be utilized to restore blood flow 2,10. Unfortunately, 
patients only become eligible for these procedures after failure of first line treatments or 
in the event of severe claudication leading to CLI 12.   Another treatment strategy, often 
prescribed as a first line treatment, is the adoption of a regimented exercise program. 
Treatment commonly consists of a minimum three month program with increasing 
walking times or distances where patients are only allowed to take breaks with the advent 
of moderate to severe leg pain 7. Adoption of such a program significantly increases both 
pain-free walking time and distance, but its efficacy is limited by poor adherence to 
exercise 10,13. Compliance in clinical trials is highly variable with one study reporting 
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compliance as low as 49% 1. Currently, PAD lacks treatment options that both treat the 
underlying disease and are available and reasonable for most patients to complete.   
1.2 Potential Treatment: Collateral Arteriogenesis  
A potential alternative approach for treatment of PAOD is to enhance the growth of 
natural bypass vessels within the peripheral circulation14. Some individual arterial trees 
are connected via small arteriole anastomoses, i.e.  collaterals15. In the distal ischemic 
hindlimb, collaterals function as the primary site of flow resistance16. Through a process 
known as collateral arteriogenesis, these vessels have the ability remodel into high 
conductance, low resistance arterial vessels, a process which can be enhanced with 
exercise 17–19.When an arterial vessel is occluded, an increased pressure gradient is 
established across collaterals upstream of the occlusion20. As a result, blood flow is 
elevated through these collaterals, causing them to act as a natural bypass routes between 
adjacent arterial trees20. Simultaneously, increased blood flow increases shear stress, 
initiating collateral arteriogenesis20,21. Endothelial cells (ECs) recruit monocytes which 
extravasate and differentiate into macrophages that orchestrate degradation of the 
extracellular matrix (ECM)22,23 . Additional cytokines released by ECs promote 
proliferation of both themselves and smooth muscle cells before new ECM is synthesized 
by local cells22,23. When completed, remodeled collaterals have the potential to restore 
sufficient perfusion to ischemic tissue downstream of an occlusion.  
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Figure 2. Arteriogenesis. Development of atherosclerotic plaques reduce blood flow to 
downstream tissues while simultaneously increasing shear stress in pre-existing collateral 
arterioles. This high shear condition activates endothelial cells, leading to the outward remodeling 
of these bypass vessel and restoring perfusion to affected tissues. 24 
  
Unfortunately, this endogenous mechanism of collateral arteriogenesis fails to 
sufficiently restore blood flow for many individuals25. Variation in both the preexisting 
collateral network and magnitude of the arteriogenic response varies significantly in 
animal models and is suspected to be similarly present with the human population15,25. 
1.3 Cell Therapy: Satellite Cell Transplantation 
To date, attempts to treat PAOD by augmenting collateral arteriogenesis have proven 
unsuccessful. Exercise treatment is efficacious, but poor compliance prevents widespread 
implementation ref. Delivery of individual arteriogenic factors (VEGF, bFGF, etc.) using 
gene therapy or recombinant proteins have appeared promising in preclinical animal 
studies and small uncontrolled clinical trials, but have proven unsuccessful in large, 
controlled clinical trials 26,27. Specifically, these therapies failed to improve pain-free 
walking distance or ankle brachial index14,28.  Alternatively, transplantation of cells 
involved in collateral remodeling are being investigated to recapitulate the benefits of 
exercise therapy9. Instead of delivering an individual growth factor, these cells can 
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potentially act as “cytokine factories”, producing a wide range of growth factors29. For 
example, bone marrow derived cells (BMC) are being investigated due to their 
recruitment to collaterals and secretion of a wide variety of cytokines (MCP-1, FGF-2, 
TGF-β, uPA, and MMPs) involved in collateral remodeling 29. Another cell type 
integrally involved in exercise is the Satellite Cell (SC), the resident stem cell responsible 
for the repair and maintenance of skeletal muscle. In response to muscle damage or 
exercise, SCs activate and differentiate into highly proliferative muscle precursor cells 
(MPCs) also known as myoblasts. With further differentiation, myoblasts exit the cell 
cycle and fuse, incorporating into regenerating or repairing myofibers30,31. SCs are 
preferentially located near capillaries within skeletal muscle and are implicated in 
signaling with endothelial cells to simultaneously promote myogenesis and 
angiogenesis32. Additionally, activated SCs and myoblasts secrete a variety of factors 
involved in collateral remodeling (MMPs, VEGF) and recruitment of monocytes (MCP-
1, MDC, FKN)23,31. Therefore, SCs and myoblasts are attractive transplantation 
candidates to recapitulate the beneficial effects of exercise to treat PAOD. 
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Figure 3. Satellite stem cell niche. Satellite cells are located on the periphery of 
myofibers between the basal lamina and sarcolemma in close proximity to the local 
microvasculature. Adapted from 33 
1.4 Project Objective 
To evaluate the potential effects of SC transplantation on arteriogenesis, it is necessary to 
establish a reliable method to isolate and culture primary murine SCs. The objective of 
this project is to build off previous work conducted to isolate and culture SCs from the 
Extensor Digitorum Longus (EDL) hindlimb muscles of mice 15 and establish reliable 
protocols to: 
1. Excise whole EDL muscles from adult mice 
2. Isolate individual viable myofibers from explanted muscles  
3. Optimize a primary culture system of live myofibers to allow sufficient expansion 
of SCs for transplantation 
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Chapter 2: Methods and Results 
2.1 Animal Husbandry  
Experimental procedures were approved by the Institutional Animal Care and Use 
Committee (IACUC) of Cal Poly. Male and Female C57Bl/6 and ICR mice aged between 
2-7 months were used for all experiments. Mice were maintained on a 12:12 hour 
light:dark cycle with ad libitum access to feed and water. 
2.2 Extensor Digitorum Longus Excision  
Mice were euthanized by cervical dislocation while anesthetized with 1-3% isoflurane 
gas with a flow rate of 0.8-1 l•min-1. Mice were placed in a supine position on a 
Styrofoam working surface, all four limbs were pinned to the surface with XXG syringes, 
and both hindlimbs were thoroughly disinfected with 70% isopropanol. The skin was 
then removed from the knee to the medial aspect of the hindpaw.  The distal tendon of the 
Tibialis Anterior (TA) and Extensor Digitorum Longus (EDL) were exposed and the 
medial aspect of the TA was freed from the tibia by cutting along its length. Next, the TA 
was resected and discarded to improve visualization before resecting the EDL. Special 
care was taken to ensure that the EDL was minimally damaged throughout the dissection 
process. Muscles were only manipulated via the proximal and distal tendons to avoid 
contact with the muscle body. To reduce the chance of stretching the muscle, 
manipulation under tension was avoided. While grasping the tendon, the muscle belly 
was allowed to sag, providing a margin of error before muscle damage would occur.  
Loss of fiber integrity at this stage, due to even minor stretching, leads to excessive fiber 
death and hypercontraction during subsequent digestion steps34,35. 
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Figure 4. Extensor Digitorum Longus excision. (A) Experimental set-up used for the excision 
of EDL muscles. Removal of skin of the hindlimb (B) exposes the TA muscle (C, grey arrow) 
and distal tendons (D) of the TA (grey arrow) and EDL (black arrow). (E) Excision of the TA (E) 
exposes the EDL muscle (black arrow). Handling only the distal tendon, the EDL is gently 
excised from tendon to tendon (F) 
2.3 Enzymatic Digestion  
Excised muscles were immediately placed in a digestion solution (3mL, 2 mg∙mL-1 type 2 
collagenase [Worthington CLS-2], 1% Penicillin-Streptomycin [Omega PS-20] in HAMS 
F10 [Fisher SH3002501] in a water bath at 37⁰C. Every ten minutes the solution was 
inverted to ensure even digestion. Muscles were incubated for 50-70 min depending upon 
muscle appearance; after 50 min, muscles were visually inspected every 5 minutes to 
avoid over-digestion of the muscle. When an EDL muscle has been properly digested, the 
muscle will shorten and widen as individual muscle fibers separate from each other and 
B 
D E F 
C A 
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structural connective tissue degrades. Distinct, shiny myofibers will begin to protrude 
from the muscle body. In the case muscles were overdigested, the muscle will appear 
fuzzy and milky colored as the surface fibers have died and hypercontracted.   
 
2.4 Mechanical Myofiber Dissociation  
All manipulations of muscles or myofibers were carried out using custom, beveled, glass 
pipettes coated with horse serum. Horse serum is critical to prevent adhesion of the 
myofibers to the pipette. Upon sufficient digestion, muscles were transferred to a 100 mm 
tissue culture dish filled with wash media (HAMS F10 supplemented with 10% FBS 
[Fisher SH3091003], 1% Pen-Strep) using the largest diameter pipette (4mm i.d.).  
Muscles were then washed with media and gently triturated to release individual fibers. 
This process was repeated with two progressively smaller pipettes (2, 0.75 mm i.d. 
respectively) until all live fibers were harvested. Live and dead/damaged fibers were 
distinguished based upon morphology. Live fibers were straight or wavy and appeared 
translucent or iridescent depending upon lighting conditions. With sufficient time in 
culture, fibers with a wavy appearance adopt a straight appearance.  If a fiber was 
severely damaged, hypercontraction would occur at the site of injury, appearing as a 
widened, milky-colored section of fiber. Often, this leads fibers to have one or more 
sharp kinks along their length. In most cases, the area of hypercontraction would extend 
along the entire length, leading to death of the fiber. Under a stereo dissecting 
microscope, using a horse serum coated P100 pipette, live myofibers were transferred 
into a series of five tissue-culture dishes with wash media (20 mL dish 1-2, 10 mL dishes 
3-5) to enrich for live fibers and reduce non-myogenic debris. Enriched fibers were plated 
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in a 60 mm tissue culture dish that was previously coated overnight with 1:1 ratio of 
collagen I (Fisher CB354249) and laminin (Life Technologies 23017015) and rinsed 
three times with wash media. The final plate was filled with 6 mL of wash media 
containing 2 ng/mL bFGF (Fisher CB40060), and incubated at 37⁰C with 5% CO2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Isolation of live myofibers. (A) Experimental setup used to isolate individual live 
myofibers. (B) Complete enzymatic digestion with myofibers protruding from the muscle (black 
arrows).  (C) Fibers are released from the muscle with mechanical dissociation resulting in (E) a 
mixed culture containing both live (black arrows) and dead (white arrows) fibers. Images were 
obtained using a stereo dissecting microscope. All scale bars are 500 μm. 
 
2.5 Myofiber Culture  
Myofiber cultures were assessed daily using a phase-contrast microscope. Typically, 
punitive Satellite Cells began migrating from fibers after two days in culture. Every three 
days, media was partially exchanged (~ X%) and supplemented with bFGF (2 ng∙mL-1); 
full media exchange was avoided to minimize fiber loss. Cultures were maintained in the 
A D 
B C E 
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initial dish until the majority of myofibers had died or the confluency reached 80%. For 
passaging, strong attachment of fibroblasts was exploited to enrich the culture for 
myogenic cells. Briefly, the media was aspirated, trypsin was added, and the culture was 
placed in the incubator. After one minute, cultures were observed to ensure selective 
liberation of myogenic cells (based on morphology) from the dish bottom. Trypsin 
(Invitrogen 25300-062) was neutralized with an equal volume of wash media and the cell 
suspension was centrifuged at 0.3 rcf for 10 minute. The resulting cell pellet was 
resuspended in wash media, and cells were plated onto coated dishes at approximately 
20% confluency. Cultures were subsequently passaged upon 80% confluency or after 5 
days 36. Myoblasts adopt a spherical or spindle-like morphology upon attaching to the 
culture dish becoming increasing differentiated with time in culture (figure 6 D).  
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Figure 6. Culture of live myofibers. (A) Representative image of a live myofiber following 
isolation. (B) At higher magnifications cell nuclei and striations can be observed (C) punitive 
Satellite cells begin to migrate from fibers after 48 hours in culture. (D) With time in culture 
myogenic cells become increasingly differentiated appearing increasingly elongated (white 
arrows). Representative images were obtained using a phase contrast microscope. All scale bars 
are 50 μm.  
 
 
 
 
 
 
 
 
 
    
A 
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Chapter 3: Discussion 3.1 Protocol Development – Extensor Digitorum Longus Excision  
PAOD affects over 8 million Americans, commonly causing pain with movement or 
exercise that leads to restricted mobility and a lower quality of life. Progression of PAOD 
can lead to amputation and is associated with increased risk of mortality. Most widely 
available treatments fail to address underlying deficits in peripheral circulation, and 
treatments such as exercise therapy which improve collateral circulation have poor 
compliance. Cell therapy has been proposed as an alternative strategy to recreate the 
beneficial effects observed with exercise. Specifically, the objective of this project was to 
isolate and culture myogenic cells for subsequent evaluation of their impact on collateral 
arteriogenesis. As a first step, EDL muscles and their proximal and distal tendons were 
exposed and subsequently excised.  The extent of connective tissue obscuring these 
tendons was highly dependent upon mouse age. In young mice both distal tendons could 
be easily visualized and accessed with minimal blunt dissection, whereas older mice 
required extensive blunt dissection to visualize distal tendons. To reduce the likelihood of 
unintentional muscle damage, young mice should be used whenever possible.   
3.2 Protocol Development – Isolation of Individual Myofibers  
The connective tissue of isolated whole muscles was degraded using a type II 
Collagenase solution, based on previous work23. Muscles were incubated without 
agitation and periodically mixed to ensure even enzyme coating for uniform muscle 
digestion35. Although gentle agitation increases SC activation during digestion of Flexor 
Digitorum Brevis muscles, this technique was not utilized37. Access to the necessary 
equipment was intermittent and risked cooling the muscle significantly below body 
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temperature. Additionally, the culture conditions used are sufficient to activate SCs34,38. 
Determination of the appropriate length of digestion proved to be a significant challenge. 
If fibers were digested for too short a time, connective tissue would be insufficiently 
degraded to allow for liberation of individual fibers from the muscle belly. When 
triturating or washing media over the muscle, superficial fibers would only separate if 
excessive force was used. Fibers liberated in this manner would commonly die due to 
damage inflicted from the process. Simultaneously, deep connective tissue would fail to 
be noticeably degraded. In contrast, excessive digestion would severely damage 
myofibers leading to a ‘kinked’ morphology. After a short time in culture these fibers die 
and develop a hypercontracted appearance34. Fibers were most effectively isolated when 
muscles were digested in the collagenase solution until the tips of superficial fibers began 
to protrude from the muscle belly. Complicating matters, the time required to reach this 
level of digestion was highly dependent upon the muscles’ physical characteristics. EDL 
muscles are commonly used to isolate live myofibers due to their thin shape and minimal 
connective tissue, both which aid enzymatic digestion. With increasing age, mouse EDL 
muscles increase in both collagen content and total volume of connective tissue39. The 
EDL muscles of adult mice (5-7 months) are significantly larger than those of young 
mice (3 months) 15.4±3.2 mg versus 9.04±0.2 mg respectively40,41. Using the described 
digestion conditions, fewer viable myofibers were harvested from older adult C57Bl/6 
mice compared with younger mice. Even with longer digestion times larger muscles 
failed to digest uniformly. Superficial fibers degraded and died while deep connective 
tissue remained intact. A potential explanation was that the digestion used was too 
aggressive leading to excessive cellular damage. In future work, this problem may be 
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addressed through the use of  type I Collagenase, combined with a longer digestion 
time42. Type I Collagenase has reduced activity of Clostripain, a proteinase that degrades 
at? arginine, making it more suitable for the digestion of delicate tissues such as liver or 
adrenal gland43. In fact, some protocols involve the use of type I Collagenase coupled 
with a longer digestion to isolate EDL and the larger Tibialis Anterior (TA) muscle34,38. 
Alternatively, the working concentration of type II Collagenase could be reduced to 
increase digestion uniformity. For either approach, it is important to account for 
significant lot-to-lot variation in enzyme activity. In fact Worthington Biochemical, the 
supplier of the type II Collagenase, only reports a minimum value of enzymatic activity 
and highly recommends sampling multiple lots for ideal digestion characteristics44. As all 
these factors modify digestion time, it is important to closely monitor the muscle 
digestion process in every procedure. 
3.3 Protocol Development – Mechanical Dissociation of Individual Myofibers 
Upon complete digestion, muscles were transferred to a fresh tissue culture dish for 
mechanical dissociation of individual fibers. As with other steps, significant effort was 
made to minimize damage to live myofibers. Surfaces in contact with myofibers were 
coated horse serum to minimize adhesion. Media was gently washed over the muscles, 
isolating fibers from the muscle body using a wide bore glass pipette. Although some 
protocols caution against trituration of the muscle, the technique proved useful for 
separating more strongly attached fibers from the muscle belly34. If used, it is critical that 
the mouth of the pipette is large enough to allow the muscle to freely enter the pipette 
without making contact with the pipette mouth. As fibers liberate from the muscle, 
smaller bore glass pipettes maintain trituration intensity. Failure of fibers to separate 
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indicates the muscle was not sufficiently digested or was severely damaged, which 
cannot be addressed by increasing the trituration force. Few fibers releasing, with 
minimal kinked or hypercontracted fibers, suggests insufficient digestion which can be 
rectified by further digesting the muscle in the collagenase solution. On the other hand, 
significant debris and hypercontraction suggest excessive fiber damage due to digestion 
or surgical error, which cannot be salvaged. If digestion and trituration are performed 
effectively, freed myofibers appear shiny and straight or wavy (a wave-like morphology 
should become straight after resting in culture overnight). Inevitably, the dissociation 
process releases a wide range of undesired cell types, including adipocytes and 
fibroblasts. To reduce contamination of the culture with these cells, live myofibers were 
identified and repeatedly transferred to fresh culture dishes. Initial use of three transfers 
proved insufficient, resulting in cultures with mixed populations of cells. Although 
unobservable, free-floating, non-myogenic cells are present in media after 3 washes45. 
The addition of two wash steps proved sufficient to significantly reduce contaminating 
cells, producing predominantly myogenic cultures45. 
3.4 Protocol Development – Live Myofiber Culture 
Isolated myofibers were immediately transferred to a culture system to selectively expand 
myogenic cells. To efficiently expand these cells, in vitro conditions must be designed to 
recapitulate as many aspects as is reasonable of the satellite cell niche. Together, the 
media and culture substrate must contain the nutrients, soluble factors, and physical cues 
necessary to support cell survival and proliferation. In this culture system, HAMs F10 
nutrient mixture was chosen as the media base because it provides a selective growth 
advantage for myogenic cells 46. In contrast, in other nutrient mixtures such as DMEM, 
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myoblasts expand more quickly, but are quickly outcompeted by fibroblasts.46. Although 
precautionary steps were taken to reduce non-myogenic cells, isolated populations of 
fibroblasts were still commonly observed, necessitating use of HAMs F10. However, 
once a highly myogenic population is established, DMEM could potentially be used to 
improve the expansion rate of the culture. 
Base media was supplemented with fetal bovine serum (FBS), an essential media 
component commonly used to culture myoblasts, that provides a relatively high 
concentration of necessary nutrients and growth factors 38,46,47. Myofibers were initially 
cultured in media containing 10% FBS, as myofibers survive longer in a relatively low 
serum environment38. Under these conditions SCs activate and migrate from fibers. Once 
fibers die in culture, the serum concentration was increased to 20% to encourage 
proliferation38. Survival of myofibers was prioritized over increased serum concentrations 
due to an observed reduction of myoblast proliferation rates following myofiber death, 
even with increased serum concentrations. This observation may be explained by a loss 
of myofiber-derived growth factors (IGF, EGF, HGF) that encourage proliferation30,31. In 
addition to FBS, the culture was supplemented with basic fibroblasts growth factor 
(bFGF or FGF2). Found in the basal lamina of skeletal muscle, bFGF is released upon 
muscle injury and has been implicated in the activation, proliferation, and reduced 
differentiation of SCs 30,31,48. 
To facilitate attachment of SCs, culture dishes were coated with two skeletal muscle 
ECM proteins, collagen I and laminin. Collagen I is a major structural component of the 
ECM that is commonly-chosen culture substrate, and is deposited by myogenic cells in 
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vitro46,49. Laminins are glycoproteins that act as linkage molecules between the basal 
lamina and sarcolemma transmitting both mechanical forces and chemical signals50. 
Interestingly, the enhanced proliferative effects of bFGF are dependent upon interactions 
with the ECM, increasing specifically with laminin as a culture substrate48. Broadly, 
interactions of SCs with the ECM are implicated in regulating a wide range of satellite 
cell behavior30.  
Using the described culture conditions myofiber derived cells were consistently 
expanded. However, cells began to increasingly exhibit a wide range of morphologies 
and variable proliferative potentials with increasing time in culture, an effect that was 
accelerated with loss of live myofibers in culture. Some cells retained a compact circular 
phenotype characteristic of minimally differentiated cells, while others exhibited an 
elongated bipolar phenotype. With increasing differentiation, the proliferative ability of 
the cells in culture declined. Once a majority of the cells appeared differentiated, the 
culture failed to appreciably expand.  
3.5 Future Work 
Future work will focus on improving culture conditions to enable long-term expansion of 
myogenic cells. Current culture conditions allow for initial expansion followed by a 
progressive loss of proliferative potential. Commonly, only 1-2 x105 cells are generated, 
limiting the number of transplantation experiments that can be completed with a single 
isolation of SCs. Additionally, current conditions result in progressive uncontrolled 
differentiation of myogenic cells. When considering cell transplantation, it is important to 
consider how in vitro differentiation will affect cellular behavior in vivo. Even three days 
in culture resulted in a tenfold reduction in the engraftment efficiency of FACS isolated 
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SCs in a dystrophic mouse model51. Similarly, in the context of peripheral ischemia, the 
function of transplanted myogenic cells may be reduced with SC differentiation. To 
address this concern, a culture system designed to limit differentiation should be 
investigated. One particularly interesting approach involves the use of a small molecule 
inhibitor of p38 MAPK signaling. p38 MAPK is part of a transcriptional regulatory 
network that influences SC self-renewal and differentiation 52. FACs isolated Human SCs 
treated with this inhibitor suppressed expression of several differentiation factors while 
maintaining exponential growth for three weeks in culture52. When implanted, these cells 
demonstrated improved engraftment compared to freshly isolated or standard culture 
conditions52. Adaptation of this system to the described single fiber culture has the 
potential to prevent in vitro differentiation, allowing long term culture expansion and 
improved in vivo behavior of myogenic cells for future transplantation studies. 
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Appendix 
Muscle Fiber Preparation and Myofiber Isolation 
Date: ______________ 
• Type II Collagenase 
• HAMS F10 Nutrient Mixture 
• Pen-Strep 
• Horse Serum (HS) 
• Fetal Bovine Serum (FBS) 
• Calf Skin Collagen Stock Solution 
• 18 MΩ Water 
• Glacial Acetic Acid 
• 60 mm Tissue Culture (TC) Dish  
• 100 mm Tissue Culture (TC) Dish 
• 15 mL Conical Tubes 
• 50 mL Conical Tubes 
• 37⁰C Water Bath 
• Rocking Platform 
• Sterile PBS 
• P1000 Micropipette 
• P1000 Micropipette Tips 
• Standard Pattern Forceps 
• Curved Iris Scissors 
• 5/45 Forceps 
• Beveled Glass Pipettes  
• Cotton swabs 
• Cotton patches 
• 500 mL, 0.22 µm Vacuum Filter System 
• Isopropyl Alcohol (IPA) 
 
Muscle Fiber Wash Plates 
1. ___ Defrost aliquot of HS 
2. ___ In TC hood, Coat 5x 100 mm TC  dishes in HS 
a. Label TC dishes 1-5 
b. Pipette 7 mL of HS into first TC dish 
c. Transfer HS between dishes 
d. Place remaining HS in 15 mL conical and place in 37⁰C water bath 
e. Aspirate excess HS from TC dishes 
3. ___ Place 20 mL of wash media into Dishes 1-2 
4. ___ Place 10 mL of wash media into Dishes 3-5 
5. ___ Warm plates in 37⁰C, 5% CO2 incubator 
 
Muscle Excision – Extensor Digitorum Longus (EDL) 
1. ___ Euthanize mouse 
2. ___ Use insulin syringe needles to secure fore and hind limbs to Styrofoam working surface 
3. ___ Thoroughly spray hindlimbs with IPA  
4. ___ Carefully remove the skin of both hindlimbs 
a. The hindlimb should be exposed from the knee joint to the midpoint of each foot 
5. ___ Carefully remove connective tissue around the Tibialis Anterior (TA) Muscle 
a. Make sure to expose the origin of the EDL at the knee 
6. ___ Create a pocket deep to the distal TA tendon below the ankle  
7. ___ Cut the distal TA tendon  
8. ___ Holding the TA by its distal tendon, pull it towards the knee cutting away connective tissue 
as  needed to separate it from the EDL 
9. ___ Cut the TA at its origin and set aside to expose the EDL 
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10. ___ Create a pocket deep to the distal EDL tendon 
11. ___ Cut the Distal EDL tendon  
12. ___ Holding the cut tendon, carefully pull EDL towards the knee separating it from the 
surrounding tissue 
a. Avoid stretching the muscle as it will damage individual myofibers 
13. ___ Cut the proximal EDL tendon 
a. Tendon to Tendon isolation is critical to maintain fiber integrity 
14. ___ Place EDL muscle into 3.0 mL of collagenase solution 
15. ___ Repeat process for contralateral hindlimb 
 
Muscle Digestion 
1. ___Place 15 mL conical with EDL muscles and collagenase in 37⁰C water bath 
2. ___ Repeatedly invert the 15 mL conical for every 10 min of incubation 
3. ___ Incubate for 40 min 
a. Digestion can take between 50-70 min depending upon collagenase activity 
4. ___ Following 50 min, remove 15 mL conical every 5 min and inspect for proper digestion 
a. Use dissecting microscope light on brightest setting for lighting 
b. When properly digested individual myofibers should begin to protrude from the surface 
of the muscle belly 
c. If the muscle appears fuzzy under a dissecting microscope or individual fibers appear fat 
and milky in color, the muscle has been overdigested 
5. ___ Upon proper digestion level, remove 15 mL conicals with HS and muscles from the water 
bath 
6. ___ Spray conicals down with IPA 
7. ___ Remove dish 1 from incubator 
8. ___ Coat glass pipettes in HS 
9. ___ Use glass pipettes to remove muscles from the 15 mL conical and transfer into the first dish 
a. Place both muscles into the first dish 
b. Place collagenase solution back into the incubator (in case further digestion is needed) 
10. ___ Use glass pipettes to dissociate muscles 
a.  Progressively use smaller bevel pipettes as the muscle becomes more dissociated 
b. The muscle should only be washed with media or gently triturated 
11. ___ Coat P1000 pipette tips with HS   
12. ___ Use a dissecting scope and P1000 pipette to pick out individual live myofibers from the dish 
a. Live myofibers will appear shiny or clear and be straight or crinkly 
b. Dead myofibers will appear opaque and bent or short  
13. ___ Place all live fibers in the next numbered dish 
a. Muscles should not remain out of the incubator for more than 15 min 
14. ___ Repeat transfer process for the other wash dishes 
15. ___ Transfer fibers as described into the  collagen and laminin coated dish 
16. ___  In the TC hood, add FGF-2 to the dish to a final concentration of 2 ng/mL 
17. ___ Place final dish back in the incubator 
a. Myoblasts should begin to migrate from the myofibers within 3 days 
18. ___ Passage cells upon local confluence or average 80% confluence 
Notes:_______________________________________________________________________________
_____________________________________________________________________________________
_____________________________________________________________________________________
_____________________________________________________________________________________ 
